Eide, C. A., Zabriskie, M. S., Savage Stevens, S. L., Antelope, O., Vellore, N. A., Than, H., . . . Deininger, M. W. (2019). Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Mutants. Cancer Cell.
Παραπομπή Chicago StyleEide, Christopher A., et al. "Combining the Allosteric Inhibitor Asciminib With Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Mutants." Cancer Cell 2019.
Παραπομπή MLAEide, Christopher A., et al. "Combining the Allosteric Inhibitor Asciminib With Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Mutants." Cancer Cell 2019.
Πρόσοχή: Οι παραπομπές μπορεί να μην είναι 100% ακριβείς.